Publications by authors named "Jennifer A Huntington"

Claim this Profile
S
Subgroup analysis of phase 2 study of ceftolozane/tazobactam in neonates and young infants with pyelonephritis.
Emmanuel Roilides, John S Bradley, Julia Lonchar, Jennifer A Huntington, Prachi Wickremasingha

Microbiol Spectr· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection.
Carl-Christian A Jackson, Jason Newland, Nataliia Dementieva, Julia Lonchar, Feng-Hsiu Su, Jennifer A Huntington

Pediatr Infect Dis J· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial.
Emmanuel Roilides, Negar Ashouri, John S Bradley, Matthew G Johnson, Julia Lonchar, Jennifer A Huntington

Pediatr Infect Dis J· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial.
Ignacio Martin-Loeches, Andrew F Shorr, Richard G Wunderink, Marin H Kollef, Jean-François Timsit, Jennifer A Huntington

Ann Intensive Care· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem.
Marin H Kollef, Jean-François Timsit, Ignacio Martin-Loeches, Richard G Wunderink, Jennifer A Huntington

Crit Care· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections.
Yihong Sun, Jia Fan, Gang Chen, Xiaofei Chen, Xiaoling Du, Jennifer A Huntington

Int J Infect Dis· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial.
David L Paterson, Matteo Bassetti, Mary Motyl, Matthew G Johnson, Mariana Castanheira, Jennifer A Huntington

J Antimicrob Chemother· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
Ignacio Martin-Loeches, Jean-François Timsit, Marin H Kollef, Richard G Wunderink, Nobuaki Shime, Jennifer A Huntington

J Antimicrob Chemother· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial.
Andrew F Shorr, Christopher J Bruno, Zufei Zhang, Erin Jensen, Wei Gao, Jennifer A Huntington

Crit Care· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
Jean-François Timsit, Jennifer A Huntington, Richard G Wunderink, Nobuaki Shime, Marin H Kollef

Crit Care· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
Matthew G Johnson, Christopher Bruno, Mariana Castanheira, Brian Yu, Jennifer A Huntington

Int J Antimicrob Agents· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Characterization of Baseline and Pseudomonas aeruginosa Isolates from a Phase 3 Nosocomial Pneumonia (ASPECT-NP) Clinical Trial.
Mariana Castanheira, Matthew G Johnson, Brian Yu, Jennifer A Huntington, Patricia Carmelitano

Antimicrob Agents Chemother· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes in Participants with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane/Tazobactam Treatment of Nosocomial Pneumonia (ASPECT-NP).
Jennifer A Huntington, Brian Yu, Linping Li, Erin Jensen, Christopher Bruno

Antimicrob Agents Chemother· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
Marin H Kollef, Martin Nováček, Ülo Kivistik, Álvaro Réa-Neto, Nobuaki Shime, Jennifer A Huntington

Lancet Infect Dis· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection.
Alan J Xiao, Jennifer A Huntington, Jianmin Long, Luzelena Caro

Int J Antimicrob Agents· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetics of 3 g of Ceftolozane/Tazobactam in Healthy Adults: A Randomized, Placebo-Controlled, Multiple-Dose Study.
Brian Yu, Adedayo Adedoyin, Ellie Hershberger, Luzelena Caro, Alan Xiao, Jennifer A Huntington

Clin Pharmacol Drug Dev· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Myra W Popejoy, Jianmin Long, Jennifer A Huntington

BMC Infect Dis· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease.
Alan J Xiao, Luzelena Caro, Myra W Popejoy, Jennifer A Huntington, Ravina Kullar

Infect Dis Ther· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
Myra W Popejoy, David L Paterson, Daniel Cloutier, Jennifer A Huntington, Benjamin Miller

J Antimicrob Chemother· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.
Jennifer A Huntington, George Sakoulas, Obiamiwe Umeh, Daniel J Cloutier, Judith N Steenbergen

J Antimicrob Chemother· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.
Alan J Xiao, Benjamin W Miller, Jennifer A Huntington, David P Nicolau

J Clin Pharmacol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.
Gurudatt Chandorkar, Jennifer A Huntington, Mark H Gotfried, Keith A Rodvold, Obiamiwe Umeh

J Antimicrob Chemother· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daptomycin therapy for osteomyelitis: a retrospective study.
Jason C Gallagher, Jennifer A Huntington, Darren Culshaw, Scott A McConnell, Minjung Yoon

BMC Infect Dis· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis